• There is significant competitive pressure in Europe and the United States due to the use of many vaccines. PEDIARIX and PENTACEL, two well-known vaccines in the US, continue to perform well. • In January 2025, ILiAD Biotechnologies, LLC announced that, following a December 2024 Type C meeting with the US FDA, it had signed a Letter of Intent with hVIVO plc to conduct a pivotal Phase 3 human challenge trial for BPZE1, an advanced next-generation intranasal pertussis vaccine. • Emerging drugs include BPZE1, BK1310/MT-2355, SIIPL Tdap, and others. • Key companies in the Pertussis market include Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others.